DUKE UNIVERSITY
Azathioprine Safety and Pharmacokinetics in Pregnant Women with Rheumatic Disease and their Infants
Azathioprine Safety and Pharmacokinetics in Pregnant Women with Rheumatic Disease and their Infants is a funding opportunity from DUKE UNIVERSITY, up to 658859, closing March 31, 2031.
Mar 31, 2031
(1704d left)Overview
ABSTRACT Pregnant women with systemic lupus and other rheumatic diseases often receive treatment with azathioprine (AZA) to control maternal inflammatory disease and optimize maternal and child outcomes. Although AZA has been the standard of care in pregnancy for over a decade, systematic evaluations of its dosing and…